| For: | Hu ZY, Ding D, Song Y, Deng YF, Zhang CM, Yu T. Molecular mechanism of pancreatic ductal adenocarcinoma: The heterogeneity of cancer-associated fibroblasts and key signaling pathways. World J Clin Oncol 2025; 16(2): 97007 [PMID: 39995552 DOI: 10.5306/wjco.v16.i2.97007] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v16/i2/97007.htm |
| Number | Citing Articles |
| 1 |
Hao Yang, Yukun Li, Jing Su, Haiyan Zhang, Wenxin Zhu, Kanger Shen, Wei Xu. UNC93B1 promotes pancreatic cancer progression through modulation of cGAS–STING signaling. Frontiers in Immunology 2026; 17 doi: 10.3389/fimmu.2026.1718849
|
| 2 |
Alessandra Rossetto, Alberto Reale. Fire in an Icy Desert: Oncolytic Virotherapy for Pancreatic Adenocarcinoma. Pharmaceutics 2026; 18(4) doi: 10.3390/pharmaceutics18040510
|
| 3 |
Robert B. Kargbo. Farnesyl Transferase Inhibitors as a Novel Strategy for Targeting KRAS-Dependent Cancers. ACS Medicinal Chemistry Letters 2025; 16(4) doi: 10.1021/acsmedchemlett.5c00113
|
| 4 |
Tina Seidel, Nupur Ohri, Markus Glaß, Yoshiaki Sunami, Lutz P. Müller, Jörg Kleeff. Stromal Cells in Early Inflammation-Related Pancreatic Carcinogenesis—Biology and Its Potential Role in Therapeutic Targeting. Cancers 2025; 17(9) doi: 10.3390/cancers17091541
|
| 5 |
Dilsa Mizrak Kaya, Yangruijue Ma, Tarik Demir, Nicole J. Altomare, Aparna Kalyan, Sheetal Kircher, Mary Mulcahy, Al B. Benson, Ruohui Chen, Devalingam Mahalingam. KRAS Subtype Modifies Outcomes with Immunomodulatory Therapy in Advanced Pancreatic Ductal Adenocarcinoma: Evidence from Early-Phase Trials. Cancers 2026; 18(13) doi: 10.3390/cancers18132037
|